![]() |
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GASTROINTESTINAL, HEPATIC, PULMONARY, AND RENAL
Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health (M.S., T.N., S.A.M., K.T., R.V.B., R.T.J.), and Biostatistics and Data Management Section, National Cancer Institute, National Institutes of Health (D.J.V.), Bethesda, Maryland; and Peptide Research Laboratories, Department of Medicine, Tulane University Health Sciences Center (S.J.H.), New Orleans, Louisiana
Received May 29, 2003; accepted July 30, 2003.
| Abstract |
|---|
|
|
|---|
GRP receptors are widely distributed in the brain, especially in the hypothalamus, the olfactory tract, dentate gyrus, and cortex. Peripherally, GRP receptors are expressed on smooth muscle cells of the intestine, stomach, and bladder and on hormone-secreting cells, as well as pancreatic acinar cells (Bunnett, 1994
; Kroog et al., 1995a
). Previous structure-function studies in the GRP-R reveal a role for the third intracellular loop (i3 loop) and the COOH terminus of the receptor in coupling to phospholipase C and receptor modulatory processes (Benya et al., 1993
, 1995
). However, little is known about the role of the receptor domains toward the N-terminal of the GRPR from the i3 loop. Only one study has analyzed a GRP-R domain N-terminal to the third intracellular loop and identified the importance of the i2 loop-DRY motif in G protein coupling and receptor internalization (Benya et al., 1994a
). In studies on muscarinic cholinergic receptors, hydrophobic residues in the central portion of the i2 loop were described to be important for G protein coupling and internalization (Moro et al., 1993
, 1994
). However, nothing is known about the function of the central portion of the i2 loop in the GRP-R or most gastrointestinal peptide hormone/neurotransmitter receptors. An amino acid sequence alignment shows conservation of the hydrophobic i2 loop residues between the Bn receptor family members and other G protein-coupled receptors (Fig. 1). Furthermore, a second recent study demonstrates that i2 loop residues in muscarinic receptors that are located between the DRY motif and the central hydrophobic residues show further evidence for a role of the i2 loop in G protein activation (Burstein et al., 1998
; Spalding and Burstein, 2001
). Therefore, in this study we have investigated, using mutagenesis, the importance of the central portion of the GRP-R i2 loop for receptor affinity, activation of PLC, GRP-R internalization, and chronic down-regulation.
|
Our results demonstrate that the central portion of the GRP-R i2 loop is important for coupling to PLC and the regulation of the two receptor modulatory processes, receptor internalization and chronic receptor down-regulation, but not for receptor affinity. Using these i2 loop mutants, we found that chronic receptor down-regulation correlates well with the mutant GRP-R's ability to activate PLC, whereas internalization does not, supporting the proposal that these two GRP receptor-modulating processes are independent processes and have different cellular mechanisms.
| Materials and Methods |
|---|
|
|
|---|
,6
-diphenylglucouril, and dithiothreitol were from Pierce Chemical (Rockford, IL). Bovine serum albumin fraction V was from ICN Pharmaceuticals Biochemicals Division (Aurora, OH). Bacitracin and 4-(2-aminoethyl)-benzenesul-fonyl-flouride were from Sigma-Aldrich (St. Louis, MO). Myo-[2-3H(N)]inositol was from PerkinElmer Life Sciences (Boston, MA). Dowex AG1-X8 anion exchange resin (100-200 mesh formate form) was from Bio-Rad (Hercules, CA). Hydro-Fluor scintillation fluid was from National Diagnostics (Atlanta, GA). KELL for Windows, version 6.0, was from Biosoft (Ferguson, MO), and GraphPad Prism 3 was from GraphPad Software Inc. (San Diego, CA).
Construction of Mutant Receptors. The pcDNA3-mouse GRP-R construct used has been described previously (Tokita et al., 2001
). Mouse GRP-R mutants were made by using the QuikChange site-directed mutagenesis kit, following the manufacturer's instruction except that the annealing temperature was 60°C, and the DpnI digestion was for 2 h. For verification of the correct nucleotide sequence the entire coding region of the GRP-R mutants was sequenced using an automated DNA sequencer (ABI PRISM 377 DNA sequencer; Applied Biosystems, Foster City, CA).
Preparation of Stable Cell Lines Expressing Mutant GRPRs. For stable transfection Balb 3T3 cells were seeded on a 10-cm dish at a density of 106 cells/dish in DMEM supplemented with 10% (v/v) FBS, 100 U/ml penicillin, and 100 µg/ml streptomycin 1 day before transfection. Cells were maintained at 37°C with a 5% CO2 atmosphere. The next morning, cells were transfected with 5 µg of plasmid DNA by lipofection (Felgner et al., 1987
) using 30 µl of LipofectAMINE reagent and 20 µl of LipofectAMINE Plus reagent in serum-free DMEM for 3 h at 37°C. Then the medium was replaced with DMEM supplemented with 10% (v/v) FBS, 100 U/ml penicillin, and 100 µg/ml streptomycin. The next day, cells were trypsinized and split into two 10-cm dishes, one which was used for a binding assay to check for expression of the GRP-R. The second 10-cm dish was trypsinized again 2 days later. Cells were plated at a range of different densities on 10-cm dishes in selecting medium [DMEM containing 10% (v/v) FBS, 100 U/ml penicillin, 100 µg/ml streptomycin, and 800 mg/l G418 sulfate]. Selecting medium was changed every 3 days. Approximately 10 days later, single colonies growing in selecting medium were picked and transferred to 24-well flasks containing keeping medium [DMEM containing 10% (v/v) FBS, 100 U/ml penicillin, 100 µg/ml streptomycin, and 300 mg/l G418 sulfate]. Clones were expanded to 75-cm2 flasks in keeping medium. Five to 10 clones were studied using 125I-[Tyr4]Bn binding studies. Clones that expressed the mutant GRP-R at a similar level as the wild-type GRP-R (reflected by similar Bmax in the binding data analysis) were selected.
Binding of 125I-[Tyr4]Bn to GRP-R-Transfected Cells. 125I-[Tyr4]Bn (2200 Ci/mmol) was prepared as described previously using iodogen and purified using high-performance liquid chromatography (Benya et al., 1994b
). Monoiodinated 125I-[Tyr4]Bn has been shown to be fully biologically active (Singh et al., 1990
). Homologous competitive binding studies using the GRP-R-transfected cells were performed as described previously (Benya et al., 1994b
). Briefly, cells were seeded on 75-cm2 flasks and split (1:5) 1 day before the experiment. Mechanically disaggregated cells were suspended for 1 h at room temperature in 300 µl of binding buffer [24.5 mM HEPES (pH 7.4), 98 mM NaCl, 6 mM KCl, 2.5 mM NaH2PO4, 5 mM sodium pyruvate, 5 mM sodium fumarate, 0.5 mM CaCl2, 1 mM MgCl2, 2.2 mM KH2PO4, 5 mM theophylline, 2 mM glutamine, 11 mM glucose, 1% (v/v) amino acid mixture, 1% (v/v) essential vitamin mixture, 0.1% (w/v) bacitracin, and 0.2% (w/v) bovine serum albumin] with 50 pM 125I-[Tyr4]Bn (2200 Ci/mmol) in the presence of the indicated concentrations of unlabeled Bn. The cell concentration was adjusted to 0.1 to 1 x 106 cells/ml to ensure that no more than 15% of the total added radioactive ligand bound. At the end of the incubation, 100 µl of cell suspension was centrifuged at 10,000g for 1 min to separate bound from unbound ligand. The pelleted bound ligand was washed twice with PBS containing 1% of bovine serum albumin and counted in a gamma counter. Nonspecific binding was the amount of radioactivity associated with GRP-R-transfected cells when the incubation mixture contained 1 µM Bn. Nonspecific binding was <15% of total binding in all experiments, and all values reported represent specific binding (i.e., total minus nonspecific binding). Analysis of binding data were performed using the least-squares analysis curvefitting program KELL (Munson and Rodbard, 1980
), which permitted comparisons in mathematically derived receptor number (Bmax) and affinity (KD) of GRP-R wild-type and mutants.
Chronic Down-Regulation of GRP-Rs. Chronic receptor down-regulation was defined as a decrease in cell surface binding after long-term agonist treatment assessed as described previously (Benya et al., 1994b
). Briefly, cells were plated in keeping medium at a density of 4 x 106 cells/185-cm2 flask. Twenty-four hours later, medium was replaced with DMEM containing 2% (v/v) FBS, 100 U/ml penicillin, 100 µg/ml streptomycin, and 300 mg/l G418 sulfate with or without 10 nM Bn. After incubation at 37°C for 24 h, cells were washed and down-regulation was measured by assessing the binding of 125I-[Tyr4]Bn to compare the number of GRP-Rs per cell in Bn-treated and nontreated cells. Binding dose-inhibition curves of Bn-treated and nontreated cells were analyzed using the curvefitting program KELL (Munson and Rodbard, 1980
). Down-regulation of mutant GRP-R was compared with wild-type GRP-R down-regulation and expressed as the percentage of decrease in mathematically derived receptor number (Bmax).
Internalization of GRP-Rs. Internalization was performed as described previously (Benya et al., 1994a
, b
; Koenig et al., 1997
) with minor modifications. Cells were transfected 3 days before the experiment and split in 24 wells 2 days before the experiment. On the day of the experiment, cells were washed with PBS and preincubated for 15 min in binding buffer [24.5 mM HEPES (pH 7.4), 98 mM NaCl, 6 mM KCl, 2.5 mM NaH2PO4, 5 mM sodium pyruvate, 5 mM sodium fumarate, 0.5 mM CaCl2, 1 mM MgCl2, 2.2 mM KH2PO4, 5 mM theophylline, 2 mM glutamine, 11 mM glucose, 1% (v/v) amino acid mixture, 1% (v/v) essential vitamin mixture, and 0.2% (w/v) bovine serum albumin] containing bacitracin (0.1%) and Sigma's protease inhibitor cocktail (1/1000). Cells were incubated with 50 pM 125I-[Tyr4]Bn in binding buffer for various times at 37°C. After incubation, the 24-well plates were put on ice. Cells were washed twice with ice-cold PBS containing 1% BSA. One milliliter of acid-stripping solution (0.2 M acetic acid and 0.5 M NaCl) was added for 10 min at 4°C. The supernatant after acid stripping was collected into the first set of counting tubes. Then PBS without calcium or magnesium was added and the aspirant saved in a second set of tubes to be counted. Finally, 250 µl of 0.05% trypsin/0.02% EDTA was added per well and after incubation for 15 min, the cells were added to the second set of tubes and both sets were counted using a CobraII autogamma counter (Packard, Sterling, VA). All data points were performed in duplicates. In all cases, parallel incubations with unlabeled bombesin to determine nonspecific binding were performed. Internalization results are expressed as percentage of the total specific acid-resistant 125I-[Tyr4]Bn binding. Analysis of internalization data was done using the GraphPad Prism software and the approach of Koenig and Edwardson (1997
). Equation 2 from their review paper (Koenig and Edwardson, 1997
) was used: Rs = [1/(ke + kr)][kr(Rs0 + Re0) + (keRs0 - krRe0)exp[- (ke + kr)t]] where ke is the constant of endocytosis, kr is the constant of recycling, Rs is the number of receptors on the cell surface, Re is the number of receptors in endosomes, and t is the time of the incubation. Rs0 (i.e., the amount of receptors in the endosomes at time t = 0) was set to zero. This yielded Rs = Rs0{kr + keexp[- (ke + kr)t]}/(ke + kr). Because Re = Rs0 - Rs the percentage of internalized receptor = 100 Re/R0 = 100(1 - Rs/Rs0). This finally ends up in the relationship % Int receptor = 100 ke{[1 - exp[-(ke + kr)t]}/(ke + kr). Nonlinear regression showed for the wild-type GRP-R a ke of 0.19 ± 0.025/min and a kr of 0.24 ± 0.040/min, which is in the range of other G protein-coupled receptors (Koenig and Edwardson, 1997
). The time needed for 80% of maximal internalization (= t80), expressed in minutes, was then derived from the relationship t80 = -ln(0.2)/(ke + kr).
Measurement of [3H]Inositol Phosphates. Changes in [3H]IP were performed as described previously (Benya et al., 1994b
). Briefly, cells were plated onto 24-well flasks at a density of 104 cells/well in keeping medium. Twenty-four hours later, cells were loaded with 3 µCi/ml myo-[2-3H(N)]inositol in DMEM containing 2% (v/v) FBS, 100 U/ml penicillin, and 100 mg/ml streptomycin for 24 h. After washing, cells were then incubated with PBS and 20 mM LiCl for 15 min at 37°C. Then cells were incubated with varying concentrations of Bn in IP buffer (135 mM NaCl, 20 mM HEPES, 2 mM CaCl2, 1.2 mM MgSO4, 1 mM EGTA, 20 mM LiCl, 11.1 mM D-glucose, 0.5% bovine serum albumin) at 37°C. After 60 min, the reaction was stopped with 1% (v/v) HCl in methanol. Total [3H]IP was isolated by anion exchange chromatography as described previously (Benya et al., 1994b
). Briefly, free [3H]inositol was removed by washing with 3 volumes of water. Disodium tetraborate (5 mM) in 60 mM sodium formate was used to remove [3H]glycerophosphoryl inositol. Total [3H]IP was eluted with 1 M ammonium formate in 100 mM formic acid. Eluates were assayed for their radioactivity after the addition of Hydro-Fluor scintillation fluid. All data points were performed in duplicate.
Preparation of Cell Membranes. For Gpp(NH)p studies, cell membranes of Balb 3T3 cells transiently transfected with wild-type or mutant GRP-R constructs 1 day before membrane preparation was used. Disaggregated cells were resuspended in homogenization buffer [50 mM Tris (pH 7.4), 0.2 mg/ml soybean trypsin inhibitor, 2 mg/ml benzamidine, and 1 mg/ml bacitracin]. Cells were homogenized on ice using a Polytron (Beckman Coulter, Inc., Fullerton, CA) at speed 6 for 30 s. The homogenate was centrifuged at 1500 rpm for 10 min in a Beckman Coulter GS-6KR centrifuge. The supernatant was recentrifuged in an RC-5B Plus (SS-34 rotor; Sorvall, Newton, CT) at 15,000 rpm for 20 min, and the pellet was resuspended in homogenization buffer at a concentration of 0.5 x 106 cells/ml and stored at -20°C.
Binding of 125I-[Tyr4]Bn to Balb 3T3 Cell Membranes. To analyze the effect of the nonhydrolyzable guanine analog Gpp(NH)p on binding of 125I-[Tyr4]Bn, cell membranes were incubated with 50 pM 125I-[Tyr4]Bn either alone or with 0.1 mM Gpp(NH)p in binding buffer (50 mM HEPES, 5 mM MgCl2·6H2O, 1 mg/ml bacitracin, and 1% BSA) for 60 min at room temperature. At the end of the incubation, 100 µl of cell suspension was added to 3 ml of cold PBS containing 1% BSA and immediately applied to a wet glass microfiber filter (GF/C; Whatman, Maidstone, UK) on a 12-well manifold (Millipore Corp., Bedford, MA). The filter was washed twice with cold PBS containing 1% BSA and counted in a gamma counter.
Statistics. Comparison of receptor affinity and receptor number between wild-type and mutant receptors was analyzed with the nonparametric Mann-Whitney U test. Comparisons of potency and efficacy for [3H]IP generation between wild-type and mutant receptors were made using the Student's two-tailed, paired t test. Regression lines, correlation coefficients, and their significance were calculated using a least-squares analysis. The time course of internalization was analyzed using a curve-fitting program in GraphPad Prism 3 (San Diego, CA). The KD and Bmax of all receptors was calculated using a least-squares curve-fitting program KELL. p values smaller than 0.05 were considered significant.
| Results |
|---|
|
|
|---|
Three different wild-type GRP-R clones that bound different amounts of radioligand were studied in detail. Affinity constants (KD) for all three clones for Bn were close to 1 nM and results for the two clones with the lowest and highest receptor number are shown in Fig. 2 and Table 1. The receptor number (Bmax) ranged between 353 and 1760 fmol/106 cells. Wild-type GRP-R clones 10 and 9 expressing 353 and 1760 fmol/106 cells, respectively, were used for further studies (Table 1). Both clones demonstrated similar potencies for Bn (EC50 values of 0.22-0.31 nM; Table 1), and stimulation by Bn resulted in similar efficacies for [3H]IP generation, with each receptor showing a 9- to 10-fold increase (Table 2). These results suggest that differences in receptor number in this range do not result in alterations in either agonist affinity, potency, or efficacy for activating phospholipase C. For each GRP-R mutation, three to four stable clones were studied by binding studies and at least one stable clone for each was identified that expressed the GRP-R point mutation near the range of the two wild-type GRP-Rs (Table 1). Five of the seven single GRP-R mutants had a similar affinity to the wild-type GRP-Rs (i.e., 0.9-1.2 nM); however, I143A and M147A had a slight, approximately 2-fold decrease in affinity for GRP as assessed by binding of 125I-[Tyr4]Bn (1.7-1.8 nM; Table 1; Fig. 2).
|
|
|
|
Because of the effect of alterations of I143A and M147A on receptor affinity (Table 1) as well as their effects on maximal phospholipase C activation as well as that of V144A, we made two double mutants, IM143.147AA and VM144.147AA. Each of the double mutants demonstrated only a 2-fold decrease in receptor affinity (Fig. 2; Table 1). However, the potency of the IM double mutant for stimulating an increase in [3H]IP was more than 300 times lower than the wild-type GRP-R, whereas the potency of the VM double mutant was not altered (Fig. 2; Table 1). The efficacy for activating phospholipase C was markedly reduced in both GRP-R double mutants. The VM double mutant stimulated about 20% and the IM double mutant only 10% of the maximal IP increase seen with the wild-type GRP-R (Table 2).
To determine whether a difference in receptor-G protein coupling contributed to the reduced ability of the GRP-R mutants to activate phospholipase C, we studied the effect of the nonhydrolzyable guanine analog Gpp(NH)p on binding of 125I-[Tyr4]Bn to cell membranes of Balb 3T3 cells that transiently expressed either wild-type or mutant GRP receptors (Fig. 3). Increasing concentrations of Gpp(NH)p decreased 125I-[Tyr4]Bn binding to cell membranes of GRP-R-expressing cells dose dependently with a half-maximal effect at approximately 1 µM Gpp(NH)p and a maximal inhibition at 0.1 mM Gpp(NH)p (data not shown). Similar decreases of 125I-[Tyr4]Bn binding to the wild-type GRP-R were seen with membranes obtained from cells expressing the R145A mutant (Fig. 3). In contrast, the 125I-[Tyr4]Bn binding to membranes expressing either the I143A, the M147A or the IM double mutant was not (I143A and IM double mutant) or significantly less (M147A) inhibited by 0.1 mM Gpp(NH)p (Fig. 3).
|
Previous studies report that wild-type GRP-R is rapidly internalized (Benya et al., 1994a
, 1994b
). Studies in other GPCRs show the second intracellular loop amino acids can play an important role in mediating this process (Moro et al., 1994
; Arora et al., 1995
). Therefore, we investigated the ability of the various GRP-R mutants and the wild-type GRP-Rs to internalize radiolabeled Bn (Table 2; Fig. 4). Both Balb 3T3 cell clones, stably transfected with wild-type GRP-R, showed a maximal internalization of 46 to 47% of the bound radioligand after 60 min of incubation with ligand (Table 2; Fig. 4), with 80% of the maximal internalization seen at 4.6 to 5.7 min (Fig. 4; Table 2). Six of the point mutations did not significantly alter maximal internalization in the stable GRP-R mutants. However, with the R145A point mutant, maximal internalization was significantly increased to 132% of the maximal seen with wild-type GRP-R internalization (Table 2; Fig. 4). All of the mutants demonstrated similar kinetics of internalization except for the M147A mutant, which demonstrated a significant prolongation of the time needed to reach 80% of maximal (i.e., t80), indicating a delayed internalization process (Table 2). The two double mutations demonstrate different effects on GRP-R internalization (Fig. 4; Table 2). Although the time needed to reach 80% of maximal internalization (i.e., t80) of the R145A mutant was not changed, the rate constant of recycling (kr) (0.11 ± 0.01 versus 0.24 ± 0.04; p < 0.01), but not the rate of constant of endocytosis (ke) (0.16 ± 0.01 versus 0.19 ± 0.02; p = 0.32), was significantly reduced by more than one-half relative to the kr of the wild-type GRP-R. This result points to an alteration of the recycling process in this mutant as the actual cause of the overall increased maximal receptor uptake. I143A and M147A demonstrated a significant prolongation of their t80 values, indicating a delayed internalization process (Table 2). The two double mutations demonstrate different effects on GRP-R internalization (Fig. 4; Table 2). Both double mutants demonstrate a decrease in the maximal internalization compared with the wild-type GRP-R (Table 2; Fig. 4). The time to reach 80% of maximal internalization was significantly prolonged with both double mutants compared with the wild-type GRP-R (Table 2). In all of the GRP-R mutants with a prolonged t80 the ke rate constant was significantly decreased relative to wild-type levels. Interestingly, in two of the kinetically altered GRP-R mutants (I143A and M147A), the kr rate constant was also significantly decreased compared with the wild-type GRP-R (0.13 ± 0.01 and 0.10 ± 0.02 versus 0.23 ± 0.04; p < 0.015).
To ascertain that the changes in internalization were not artifacts of the selection process used to isolate stable clones, we repeated the experiments in Balb 3T3 cells transiently transfected with the wild-type GRP-R or with the selected mutants that had altered internalization in the stably transfected cells. Balb 3T3 cells that were transiently transfected with the wild-type GRP-R construct showed a maximal internalization of 31 ± 3.5% of the radioligand at 120 min (Fig. 4, inset). The stimulatory effect on maximal internalization seen with the stable GRP-R mutants (Fig. 4) by the R145A mutation was confirmed in the transient GRP-R-transfected cells (39 ± 4% at 120 min) (Fig. 4, inset). The inhibitory effect of the IM double mutant (21 ± 5.4% at 120 min) was also confirmed. No other single or double GRP-R mutant showed a significant effect on maximal internalization.
Previous studies demonstrate the wild-type GRP-R can undergo chronic down-regulation; however, the molecular mechanism is largely unknown. To determine the possible importance of the GRP-R i2 loop in activating processes involved in mediating chronic down-regulation we determined the effect of these GRP-R mutations on chronic GRP-R down-regulation (Fig. 5). To assess down-regulation, after preincubation with Bn, homologous competitive binding assays were performed to assess remaining cell surface receptors. Similar to a previous study with the GRP-R (Benya et al., 1994b
), no significant change in the affinity (KD) of the receptor for bombesin was seen during down-regulation, demonstrating that the down-regulation reflects loss in cell membrane receptor protein. Wild-type GRP-R was down-regulated by 61.3 ± 3.4% after a 24-h incubation with Bn (Table 2; Fig. 5). The magnitude of the chronic down-regulation was altered in three of the seven single GRP-R mutants and in both double mutants (Table 2). In contrast to wild-type GRP-R, the A142S, the I143A, and the M147A GRP-R mutants showed a significant decrease (40-60% of control) in maximal down-regulation (Fig. 5; Table 2). Down-regulation of the VM double mutant also was decreased by 38% and the IM double mutation completely inhibited all down-regulation (Fig. 5; Table 2).
|
Previous studies (Benya et al., 1993
, 1994a
) have demonstrated that GRP-R internalization and down-regulation are at least partially dependent on phospholipase C activation. To analyze this relationship in more detail, we correlated the magnitude of maximal phospholipase C activation with the wild-type GRP-R and different GRP-R mutants as assessed by maximal stimulation of [3H]IP with the extent of maximal internalization (Fig. 6, top) and extent of maximal receptor down-regulation (Fig. 6, bottom). There was only a weak (p = 0.04) association between the maximal increase in [3H]IP and the degree of internalization. This conclusion was further supported by the result that almost maximal internalization occurred with minimal changes in [3H]IP, which was reflected in the low slope (i.e., 0.3x) of the regression equation (Fig. 6, top). In contrast, the extent of maximal activation of phospholipase C showed a significant (p = 0.008) correlation with the maximal degree of chronic GRP-R down-regulation (Fig. 6, bottom). This latter conclusion was further supported by the correlation of the different GRP-R mutants to stimulate maximal changes in these two processes which showed a proportional increase in [3H]IP with increasing down-regulation (Fig. 6, bottom), resulting in a slope of 0.8 for the regression equation, which was not significantly different from unity.
|
| Discussion |
|---|
|
|
|---|
In general, a number of our findings support the conclusion that alterations in the central portion of the GRP-R i2 loop have a minimal effect on receptor affinity; however, this receptor region was important for activation of intracellular mediators. First, of the seven receptor mutations of the central portion of the GRP-R i2 loop examined, only two showed a small decrease (i.e., <2-fold) in receptor affinity and/or potency for activating the receptor and stimulating PLC activity. Second, even two double mutants of the two amino acids showing a small decrease in receptor affinity when present alone, had a minimal effect on receptor affinity. Third, one double mutant [IM143.147AA], however, demonstrated a greater than 300-fold decrease in potency for activating PLC, demonstrating these amino acids in concert can play an important role in coupling of the GRP receptor to PLC. Fourth, five of the single mutants and each of the double mutants showed a decreased efficacy for activating PLC, demonstrating the importance of this receptor region for maximal coupling and activation of this intracellular receptor cascade. Of note, it was shown for all the GRP receptors studied that the likely cause for the decreased coupling to PLC is altered receptor-G protein coupling. This conclusion is supported by the comparison of the effect of Gpp(NH)p on the different mutants with the change in binding affinity. Each of the GRP-R mutants examined showing a decrease in affinity had defective G protein coupling, whereas the GRP-R mutants without altered affinity retained G protein coupling.
Our results of effects of mutations in the GRP-R's i2 loop on binding to Bn and on the potency have both similarities and differences to data from the literature. The findings that the single mutants I143A and M147A[GRP-R] and both double mutants reveal not only a slight but significant shift in affinity but also an uncoupling from the G protein and thereby from PLC, correspond well with Lefkowitz and Costa's ternary complex model (Lefkowitz et al., 1993
). This model predicts a diminished affinity of the receptor to the agonist for the case of a decreased G protein-coupling ability of the receptor. These data also agree with results on corresponding mutations in the histamine H2 receptor (Smit et al., 1996
) and the angiotensin II receptor (Modrall et al., 2001
) that shows a decrease in affinity to agonist binding as well as a decreased ability to stimulate PLC. In contrast to our result, with the M147A mutant in the GnRH receptor (Arora et al., 1995
), the thromboxane A2 receptor (Zhou et al., 1999
), and the angiotensin II receptor (Modrall et al., 2001
), a corresponding mutation to our M147A caused either no change or a small decrease in affinity relative to the wild-type receptor. There are no data in the literature to compare our finding that two of our mutants, the I143A[GRP-R] and the IM143.147AA double mutant, cause a shift in the potency for receptor activation. However, there are studies on corresponding mutations to M147A[GRP-R] in the m1 muscarinic cholinergic receptor (Shockley et al., 1997
) and in the histamine H2 receptor (Smit et al., 1996
) that both found decreases in potency for activation of PLC and adenylyl cyclase, respectively. In contrast, we did not find a significant alteration in potency for activating PLC with this mutation in the GRP-R. Several studies in other GPCRs have investigated the effect of i2 loop mutations on the efficacy of the ligand-stimulated 2nd messenger production. Our findings are in agreement with results of studies on corresponding mutations in the histamine H2, GnRH, thromboxane A2, angiotensin II, and the human m5 muscarinic cholinergic receptor (Arora et al., 1995
; Smit et al., 1996
; Burstein et al., 1998
; Zhou et al., 1999
; Modrall et al., 2001
). From studies of the m1 muscarinic and
2-adrenergic receptor mutants, Moro et al. (1993
, 1994
) proposed a new motif for G protein coupling of these receptors [DRYXXV(I)XXPL, where X is any amino acid and L is leucine or another bulky, hydrophobic amino acid]. In the GRP-R, the Ile-143 and Met-147 correspond to the V(I) and the L in this motif. Our findings that the I143A and M147A single mutants as well as the IM double mutant have markedly reduced efficacy for stimulation of PLC are in agreement with this model. There is only one study (Blin et al., 1995
) that has investigated residues next to the hydrophobic residues discussed above, such as Ala-142, Val-144, and Asp-148, which we found are also important for maximal efficacy for PLC activation. In this study (Blin et al., 1995
), corresponding mutant to our A142S[GRP-R] in the m3 muscarinic cholinergic receptor suggested a role for this residue in G protein coupling. Interestingly, in our study Pro-146, which is well conserved in this position in a number of GPCRs (Fig. 1), did not show any changes in receptor affinity or activation when mutated to alanine. This is in agreement with data from studies on the m1 muscarinic cholinergic receptor (Moro et al., 1993
) but is different from data on the m5 muscarinic cholinergic receptor (Burstein et al., 1998
). The notion that several adjacent residues of the i2 loop have a function in coupling to signaling processes downstream of the GRP receptor, agrees with the recent findings on the protein structure of GPCRs in which it was discussed that the i3 loop interacts with G proteins and that the i2 loop is in close contact to the i3 loop in the ground state of the GPCR and loops away once the receptor is activated (Zeng et al., 1999
; Palczewski et al., 2000
; Spalding and Burstein, 2001
). Mutations in the i2 loop could, therefore, interfere with the dynamic actions of the i2 loop and thereby decrease the GPCR's capability to interact properly with the G protein. This proposal is further supported by our preliminary three-dimensional modeling data of the GRP-R using the rhodopsin three-dimensional structure as a template (data not shown). Residues Ile-143 and Val-144 of the i2 loop are located close to the N-terminal part of the third intracellular loop at a distance that could allow interactions to occur.
After activation, wild-type GRP-R, similar to other GPCRs, undergoes internalization (Pandol et al., 1982
; Benya et al., 1994a
, b
), down-regulation (Benya et al., 1994b
, 1995
, 2000
) and desensitization (Benya et al., 1994b
, 1995
, 2000
). Our results show that amino acid residues of the central portion of the i2 loop play an important role in mediating both internalization and down-regulation of the GRP-R. Alterations of three residues (R145A, M147A, and IM143.147AA) resulted in changes in internalization rate and/or magnitude. Whereas no single alteration of a residue decreased the magnitude of maximal internalization the alteration of one residue (Arg-145) caused an increase in maximal internalization suggesting that the presence of Arg-145 was having a restraining effect on internalization in the wild-type receptor. Interestingly, computer fitting of the internalization data of the R145A mutant using the models of Koenig and Edwardson (1997
) revealed that the rate constant of recycling (kr) but not the rate constant of endocytosis (ke) was significantly reduced by more than one-half relative to the kr of the wild-type GRP-R. This result points to an alteration of the recycling process in this mutant as possibly contributing to the overall increased maximal receptor internalization seen. There are no data in the literature about an effect of a corresponding mutation in another receptor on internalization. However, using the receptor selection and amplification technology (R-SAT) on the i2 loop of the m5 muscarinic cholinergic receptor, Burstein et al. (1998
) suggested a pivotal role of the corresponding residue to Arg-145 in switching between active and inactive conformations of this receptor. Because in their hands substituting this residue by any amino acid rendered the m5 cholinergic receptor constitutively active, they hypothesized that the native arginine residue in this position is important for "switching off" the receptor. We show that Arg-145 of mutated GRP-R is neither changed in the potency nor the efficacy for PLC activation. Nevertheless, our finding that this residue inhibits internalization in combination with data of Burstein et al. (1998
) is of interest in the light of recent findings that the process of receptor endocytosis by itself modulates the activation of intracellular growth cascades (Pierce and Lefkowitz, 2001
). The inhibitory effect of the mutations on the Ile-143 and the Met-147, seen in both single and double mutants, corresponds well with studies on the m1 muscarinic cholinergic, the
2-adrenergic, and the GnRH receptor (Moro et al., 1994
; Arora et al., 1995
; Shockley et al., 1997
). In contrast, a study on the angiotensin II receptor showed no effect on internalization (Modrall et al., 2001
). The greater effect on internalization of the Ile-143 and the Met-147 mutations together, than either alone on internalization rate and magnitude, suggests a synergistic role of these amino acid residues and is in agreement with data on the m1 muscarinic cholinergic receptor (Moro et al., 1994
). The changed kinetics of the internalization process in these mutants (i.e., the prolonged t80 values) correlated well with significantly decreased endocytic rate constants (ke) in all of these mutants. Interestingly, the single mutants also showed receptor constants (kr) that apparently had a smaller impact on the t80 time than the decreased ke constants.
Chronic receptor down-regulation describes the agonist-dependent loss of receptor binding sites on the cell membrane after long-term incubation with the agonist and leads to an attenuation of the signal transduction by this receptor. Different molecular mechanisms in concert account for this process, including intracellular degradation of receptor protein, long-term storage of receptors in intracellular vesicles, and various mechanisms of regulation of receptor mRNA levels (von Zastrow, 2001
). Studies that examine the structure-function relationship of chronic receptor down-regulation are rare. In our study, alterations of three residues alone (A142S, I143A, and M147A) or in combination (IM143.147AA) reduced the ability of the GRP-R to undergo chronic down-regulation. Our results with the M147 mutation in the GRP-R differ from those with the angiotensin II receptor (Modrall et al., 2001
) and histamine H2 receptor (Smit et al., 1996
) where a comparable mutation did not reduce the extent of chronic receptor down-regulation. However, they are similar to results of a comparable I143A mutation, M147A mutation, or double mutation (IM143.147AA) in the m1 human muscarinic cholinergic receptor (Shockley et al., 1997
). These results demonstrate that in addition to serines, threonines, and a protein kinase C consensus sequence in the COOH terminus of the GRP-R (Benya et al., 1993
), residues in the i2 loop of the GRP-R are important in mediating chronic down-regulation as well as receptor internalization.
The current study of the GRP-R structure-function of the i2 loop provides some insights into the possible relationship between GRP-R internalization and chronic down-regulation as well as the possible role of PLC activation in mediating these two receptor modulatory processes. With the
2-adrenergic receptor, chronic receptor down-regulation was proposed to be important in mediating chronic desensitization, whereas both of these processes were proposed to be independent of receptor internalization (Proll et al., 1993
). One study proposed that GRP-R internalization mediates chronic receptor down-regulation and desensitization (Pandol et al., 1982
). However, other studies involving mutant GRP-Rs, wild-type GRP-R, and the closely related NMB-receptor propose that chronic GRP-R down-regulation is closely linked to chronic desensitization, whereas internalization is likely not coupled to these processes (Benya et al., 1994c
, 2000
). Support is provided in our study for GRP-R internalization and chronic down-regulation not being closely coupled processes because of the different effects of i2 loop mutations on the two receptor modulatory processes. Whereas the magnitude of down-regulation was decreased by various single mutations (I143A, V144A, and M147A), the magnitude of internalization was unaltered. Conversely, the R145A mutation augmented internalization, whereas it had no effect on chronic down-regulation. Conflicting results are reported on the role of second messengers and phosphorylation in mediating receptor internalization and down-regulation. Studies on both
2-adrenergic receptors (Strader et al., 1987
; Cheung et al., 1989
; Cheung et al., 1990
; Campbell et al., 1991
) and PLC-linked muscarinic cholinergic receptors (Thompson and Fisher, 1990
; Lameh et al., 1992
) have provided differing results for their role in mediating internalization, as have studies investigating the relationship between PLC activation and epidermal growth factor-receptor internalization (Chen et al., 1987
; Honegger et al., 1987
; Chen et al., 1989
). With
-adrenergic receptor, receptor phosphorylation may play an important role in each of these receptor modulating processes. A previous study showed GRP-Rs deficient in COOH terminal phosphorylation sites have impaired internalization (Benya et al., 1993
). Studies on the GRP-R examining agonist-dependent phosphorylation of the receptor revealed a rapid, nonprotein kinase C (PKC)-dependent phase of phosphorylation (<10 min) that can be differentiated from a phase that is PKC-triggered late phosphorylation (Kroog et al., 1995b
). In vitro studies suggested that the best candidate for the rapid phase of phosphorylation is G protein-coupled receptor kinase 2 (Kroog et al., 1999
). Because >90% of the internalization process has reached its maximum by 10 min, G protein-coupled receptor kinase 2 would be a good candidate for the GRP-R phosphorylation that is necessary for the internalization process to occur. On the other hand, chronic receptor down-regulation likely is a process that requires PKC-mediated phosphorylation of the GRP receptor because this process has much slower kinetics than from internalization (Benya et al., 1994b
), and mutation of the C-terminal PKC consensus site abolished this process (Benya et al., 1995
). Studies of the wild-type GRP-R as well as various mutant GRP-Rs have proposed that GRP-R chronic down-regulation and internalization are mediated by different intracellular mediators and PLC activation is not equally important in both of these receptor modulatory processes (Benya et al., 1993
, 1994a
, 1995
, 2000
). Using GRP-R mutants that do not activate PLC-cascades, GRP-R mutants with PKC consensus site lacking, various COOH-terminal truncation GRP-R mutants and various glycosylation-deficient GRP-R mutants (Benya et al., 1993
, 1994a
, 1995
, 2000
), it has been shown that maximal PLC activation is not needed for maximal internalization. The results in the present study provide support for these proposals. In the present study a GRP-R mutant (IM143.147AA) with only 11% of the wild-type's ability to activate PLC was able to reach more than 70% of the maximal internalization of the wild-type GRP-R (Benya et al., 1993
, 1994a
, 1995
, 2000
). Although there was a strong correlation (r = 0.95) between the maximal stimulation of total IP with the rate of endocytosis (rate constant ke), there was only a weak correlation (p = 0.04) between the extent of GRP-R internalization and the maximal extent of phospholipase C activation for the various i2 loop mutants. Furthermore, almost maximal internalization (i.e., 90%) occurred with minimal changes in PLC activity. In contrast, the extent of maximal activation of phospholipase C and the maximal degree of chronic receptor down-regulation demonstrated a highly significant relationship (p = 0.008), and the slope of the repression equation was almost unity, demonstrating progressive increases in PLC activity resulted in similar increases in down-regulation.
In conclusion, we show that amino acid residues of the central portion of the i2 loop of the GRP-R are important in coupling the receptor to G proteins and to PLC, in mediating receptor internalization and chronic receptor down-regulation; however, they are not essential for high-affinity receptor binding. Our results are consistent with the proposal that maximal activation of the PLC cascade by GRP-R is essential for chronic GRP receptor down-regulation, but not or only minimally required in GRP receptor internalization. They are also consistent with the proposal that chronic GRP receptor down-regulation is not mediated by GRP receptor internalization and these are not coupled processes.
| Footnotes |
|---|
ABBREVIATIONS: DR, down-regulation; Bn, bombesin; GRP, gastrin-releasing peptide; GRP-R, gastrin-releasing peptide receptor; i2 loop, second intracellular loop; NMB, neuromedin B; PLC, phospholipase C; IP, inositol phosphate; DMEM, Dulbecco's modified Eagle's medium; FBS, fetal bovine serum; PBS, phosphate-buffered saline; BSA, bovine serum albumin; Gpp(NH)p, guanosine 5'-(
,
-imido)triphosphate; GPCR, G protein-coupled receptor; PKC, protein kinase C.
Address correspondence to: Dr. Robert T. Jensen, Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bldg. 10, Rm. 9C-103, 10 Center Dr., MSC 1804, Bethesda, MD. E-mail: robertj{at}bdg10.niddk.nih.gov
| References |
|---|
|
|
|---|
Arora KK, Sakai A, and Catt KJ (1995) Effects of second intracellular loop mutations on signal transduction and internalization of the gonadotropin-releasing hormone receptor. J Biol Chem 270: 22820-22826.
Benya RV, Akeson M, Mrozinski J, Jensen RT, and Battey JF (1994a) Internalization of the gastrin-releasing peptide receptor is mediated by phospholipase C-dependent and -independent processes. Mol Pharmacol 46: 495-501.[Abstract]
Benya RV, Fathi Z, Battey JF, and Jensen RT (1993) Serines and threonines in the gastrin-releasing peptide receptor carboxyl terminus mediate internalization. J Biol Chem 268: 20285-20290.
Benya RV, Fathi Z, Pradhan T, Battey JF, Kusui T, and Jensen RT (1994b) Gastrin-releasing peptide receptor-induced internalization, down-regulation, desensitization and growth: Possible role of cAMP. Mol Pharmacol 46: 235-245.[Abstract]
Benya RV, Kusui T, Battey JF, and Jensen RT (1994c) Desensitizaton of neuromedin B receptors (NMB-R) on native and NMB-R transfected cells involves down-regulation and internalization. J Biol Chem 269: 11721-11728.
Benya RV, Kusui T, Battey JF, and Jensen RT (1995) Chronic desensitization and down-regulation of the gastrin-releasing peptide receptor are mediated by a protein kinase C-dependent mechanism. J Biol Chem 270: 3346-3352.
Benya RV, Kusui T, Katsuno T, Tsuda T, Mantey SA, Battey JF, and Jensen RT (2000) Glycosylation of the gastrin-releasing receptor expression, G protein coupling and receptor modulatory processes. Mol Pharmacol 58: 1490-1501.
Blin N, Yun J, and Wess J (1995) Mapping of single amino acid residues required for selective activation of Gq/11 by the m3 muscarinic acetylcholine receptor. J Biol Chem 270: 17741-17748.
Bunnett N (1994) Gastrin-releasing peptide, in Gut Peptides (Walsh JH and Dockray GJ eds) pp 423-445, Raven Press, New York.
Burstein ES, Spalding TA, and Brann MR (1998) The second intracellular loop of the m5 muscarinic receptor is the switch which enables G-protein coupling. J Biol Chem 273: 24322-24327.
Campbell PT, Hnatowich M, O'Dowd BF, Caron MG, Lefkowitz RJ, and Hausdorff WP (1991) Mutations of the human beta 2-adrenergic receptor that impair coupling to Gs interfere with receptor down-regulation but not sequestration. Mol Pharmacol 39: 192-198.[Abstract]
Chen WS, Lazar CS, Lund KA, Welsh JB, Chang CP, Walton GM, Der CJ, Wiley HS, Gill GN, and Rosenfeld MG (1989) Functional independence of the epidermal growth factor receptor from a domain required for ligand-induced internalization and calcium regulation. Cell 59: 33-43.[CrossRef][Medline]
Chen WS, Lazar CS, Poenie M, Tsien RY, Gill GN, and Rosenfeld MG (1987) Requirement for intrinsic protein tyrosine kinase in the immediate and late actions of the EGF receptor. Nature (Lond) 328: 820-823.[CrossRef][Medline]
Cheung AH, Dixon RA, Hill WS, Sigal IS, and Strader CD (1990) Separation of the structural requirements for agonist-promoted activation and sequestration of the beta-adrenergic receptor. Mol Pharmacol 37: 775-779.[Abstract]
Cheung AH, Sigal IS, Dixon RA, and Strader CD (1989) Agonist-promoted sequestration of the beta 2-adrenergic receptor requires regions involved in functional coupling with Gs. Mol Pharmacol 35: 132-138.[Abstract]
Felgner PL, Gadek TR, Holm M, Roman R, Chan HW, Wenz M, Northrop JP, Ringold GM, and Danielsen M (1987) Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci USA 84: 7413-7417.
Fraser CM, Chung FZ, Wang CD, and Venter JC (1988) Site-directed mutagenesis of human beta-adrenergic receptors: substitution of aspartic acid-130 by asparagine produces a receptor with high-affinity agonist binding that is uncoupled from adenylate cyclase. Proc Natl Acad Sci USA 85: 5478-5482.
Fraser CM, Wang CD, Robinson DA, Gocayne JD, and Venter JC (1989) Site-directed mutagenesis of m1 muscarinic acetylcholine receptors: conserved aspartic acids play important roles in receptor function. Mol Pharmacol 36: 840-847.[Abstract]
Honegger AM, Dull TJ, Felder S, Van Obberghen E, Bellot F, Szapary D, Schmidt A, Ullrich A, and Schlessinger J (1987) Point mutation at the ATP binding site of EGF receptor abolishes protein-tyrosine kinase activity and alters cellular routing. Cell 51: 199-209.[CrossRef][Medline]
Jensen RT (1994) Receptors on pancreatic acinar cells, in Physiology of the Gastrointestinal Tract, 3rd ed. (Johnson LR, Jacobson ED, Christensen J, Alpers DH, and Walsh JH eds) pp 1377-1446, Raven Press, New York.
Jones PG, Curtis CA, and Hulme EC (1995) The function of a highly-conserved arginine residue in activation of the muscarinic M1 receptor. Eur J Pharmacol 288: 251-257.[CrossRef][Medline]
Koenig JA and Edwardson JM (1997) Endocytosis and recycling of G protein-coupled receptors. Trends Pharmacol Sci 18: 276-287.[Medline]
Koenig JA, Edwardson JM, and Humphrey PP (1997) Somatostatin receptors in Neuro2A neuroblastoma cells: ligand internalization. Br J Pharmacol 120: 52-59.[CrossRef][Medline]
Kroog GS, Jensen RT, and Battey JF (1995a) Mammalian bombesin receptors. Med Res Rev 15: 389-417.[Medline]
Kroog GS, Jian X, Chen L, Northup JK, and Battey JF (1999) Phosphorylation uncouples the gastrin-releasing peptide receptor from Gq. J Biol Chem 274: 36700-36706.
Kroog GS, Sainz E, Worland PJ, Akeson MA, Benya RV, Jensen RT, and Battey JF (1995b) The gastrin releasing peptide receptor is rapidly phosphorylated by a kinase other than protein kinase C after exposure to agonist. J Biol Chem 270: 8217-8224.
Lameh J, Philip M, Sharma YK, Moro O, Ramachandran J, and Sadëe W (1992) Hm1 muscarinic cholinergic receptor internalization requires a domain in the third cytoplasmic loop. J Biol Chem 267: 13406-13412.
Lefkowitz RJ, Cotecchia S, Samama P, and Costa T (1993) Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins. Trends Pharmacol Sci 14: 303-307.[CrossRef][Medline]
McClue SJ, Baron BM, and Harris BA (1994) Activation of Gi protein by peptide structures of the muscarinic M2 receptor second intracellular loop. Eur J Pharmacol 267: 185-193.[CrossRef][Medline]
Modrall JG, Nanamori M, Sadoshima J, Barnhart DC, Stanley JC, and Neubig RR (2001) ANG II type 1 receptor downregulation does not require receptor endocytosis or G protein coupling. Am J Physiol 281: C801-C809.
Moro O, Lameh J, Hogger P, and Sadee W (1993) Hydrophobic amino acid in the i2 loop plays a key role in receptor-G protein coupling. J Biol Chem 268: 22273-22276.
Moro O, Shockley MS, Lameh J, and Sadee W (1994) Overlapping multi-site domains of the muscarinic cholinergic Hm1 receptor involved in signal transduction and sequestration. J Biol Chem 269: 6651-6655.
Munson PJ and Rodbard D (1980) LIGAND: a versatile computerized approach for characterization of ligand-binding systems. Anal Biochem 107: 220-229.[CrossRef][Medline]
Needleman SB and Wunsch CD (1970) A general method applicable to the search for similarities in the amino acid sequence of two proteins. J Mol Biol 48: 443-453.[CrossRef][Medline]
Palczewski K, Kumasaka T, Hori T, Behnke CA, Motoshima H, Fox BA, Le Trong I, Teller DC, Okada T, Stenkamp RE, et al. (2000) Crystal structure of rhodopsin: a G protein-coupled receptor. Science (Wash DC) 289: 739-745.
Pandol SJ, Jensen RT, and Gardner JD (1982) Mechanism of [Tyr4]bombesin-induced desensitization in dispersed acini from guinea pig pancreas. J Biol Chem 257: 12024-12029.
Pierce KL and Lefkowitz RJ (2001) Classical and new roles of beta-arrestins in the regulation of G-protein-coupled receptors. Nat Rev Neurosci 2: 727-733.[CrossRef][Medline]
Proll MA, Clark RB, and Butcher RW (1993) Beta 2-adrenergic receptor mutants reveal structural requirements for the desensitization observed with long-term epinephrine treatment. Mol Pharmacol 44: 569-574.[Abstract]
Rozengurt E (1988) Bombesin-induction of cell proliferation in 3T3 cells. Specific receptors and early signaling events. Ann NY Acad Sci 547: 277-292.[Medline]
Schreiber RE, Prossnitz ER, Ye RD, Cochrane CG, and Bokoch GM (1994) Domains of the human neutrophil N-formyl peptide receptor involved in G protein coupling. Mapping with receptor-derived peptides. J Biol Chem 269: 326-331.
Shockley MS, Burford NT, Sadee W, and Lameh J (1997) Residues specifically involved in down-regulation but not internalization of the m1 muscarinic acetylcholine receptor. J Neurochem 68: 601-609.[Medline]
Singh P, Draviam E, Guo YS, and Kurosky A (1990) Molecular characterization of bombesin receptors on rat pancreatic acinar AR42J cells. Am J Physiol 258: G803-G809.
Sinnett-Smith J, Zachary I, Valverde AM, and Rozengurt E (1993) Bombesin stimulation of p125 focal adhesion kinase tyrosine phosphorylation. Role of protein kinase C, Ca2+ mobilization and the actin cytoskeleton. J Biol Chem 268: 14261-14268.
Smit MJ, Roovers E, Timmerman H, van de Vrede Y, Alewijnse AE, and Leurs R (1996) Two distinct pathways for histamine H2 receptor down-regulation. H2 Leu124
Ala receptor mutant provides evidence for a cAMP-independent action of H2 agonists. J Biol Chem 271: 7574-7582.
Spalding TA and Burstein ES (2001) Constitutively active muscarinic receptors. Life Sci 68: 2511-2516.[CrossRef][Medline]
Strader CD, Sigal IS, Blake AD, Cheung AH, Register RB, Rands E, Zemcik BA, Candelore MR, and Dixon RA (1987) The carboxyl terminus of the hamster beta-adrenergic receptor expressed in mouse L cells is not required for receptor sequestration. Cell 49: 855-863.[CrossRef][Medline]
Tache Y, Melchiorri P, and Negri L (1988) Bombesin-like peptides in health and disease. Ann NY Acad Sci 547: 1-541.
Thompson AK and Fisher SK (1990) Relationship between agonist-induced muscarinic receptor loss and desensitization of stimulated phosphoinositide turnover in two neuroblastomas: methodological considerations. J Pharmacol Exp Ther 252: 744-752.
Thompson JB, Wade SM, Harrison JK, Salafranca MN, and Neubig RR (1998) Cotransfection of second and third intracellular loop fragments inhibit angiotensin AT1a receptor activation of phospholipase C in HEK-293 cells. J Pharmacol Exp Ther 285: 216-222.
Tokita K, Katsuno T, Hocart SJ, Coy DH, Llinares M, Martinez J, and Jensen RT (2001) Molecular basis for selectivity of high affinity peptide antagonists for the gastrin-releasing peptide receptor. J Biol Chem 276: 36652-36663.
Tseng MJ, Coon S, Stuenkel E, Struk V, and Logsdon CD (1995) Influence of second and third cytoplasmic loops on binding, internalization and coupling of chimeric bombesin/m3 muscarinic receptors. J Biol Chem 270: 17884-17891.
Tsuda T, Kusui T, and Jensen RT (1997) Neuromedin B receptor activation causes tyrosine phosphorylation of p125FAK by a phospholipase C independent mechanism which requires p21rho and integrity of the acini cytoskeleton. Biochemistry 36: 16328-16337.[CrossRef][Medline]
von Zastrow M (2001) Endocytosis and downregulation of G protein-coupled receptors. Parkinsonism Relat Disord 9: 265-271.
Wang CD, Buck MA, and Fraser CM (1991) Site-directed mutagenesis of
2A-adrenergic receptors: identification of amino acids involved in ligand binding and receptor activation by agonists. Mol Pharmacol 40: 168-179.[Abstract]
Wong SK, Parker EM, and Ross EM (1990) Chimeric muscarinic cholinergic: beta-adrenergic receptors that activate Gs in response to muscarinic agonists. J Biol Chem 265: 6219-6224.
Zeng FY, Hopp A, Soldner A, and Wess J (1999) Use of a disulfide cross-linking strategy to study muscarinic receptor structure and mechanisms of activation. J Biol Chem 274: 16629-16640.
Zhou H, Yan F, Yamamoto S, and Tai HH (1999) Phenylalanine 138 in the second intracellular loop of human thromboxane receptor is critical for receptor-G-protein coupling. Biochem Biophys Res Commun 264: 171-175.[CrossRef][Medline]
This article has been cited by other articles:
![]() |
R. T. Jensen, J. F. Battey, E. R. Spindel, and R. V. Benya International Union of Pharmacology. LXVIII. Mammalian Bombesin Receptors: Nomenclature, Distribution, Pharmacology, Signaling, and Functions in Normal and Disease States Pharmacol. Rev., March 1, 2008; 60(1): 1 - 42. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. R. Grider Gastrin-releasing peptide is a modulatory neurotransmitter of the descending phase of the peristaltic reflex Am J Physiol Gastrointest Liver Physiol, December 1, 2004; 287(6): G1109 - G1115. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-X. Tao and D. L. Segaloff Functional Characterization of Melanocortin-3 Receptor Variants Identify a Loss-of-Function Mutation Involving an Amino Acid Critical for G Protein-Coupled Receptor Activation J. Clin. Endocrinol. Metab., August 1, 2004; 89(8): 3936 - 3942. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||